Inari Medical reports the financing provides Inari with capital to commercialize its innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”), a leading cause of death and disability worldwide affecting over 10 million patients annually1.

To date, Inari Medical has developed the FlowTriever and ClotTriever Systems, both of which are designed to enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs.

“We are fortunate to have the support of a strong consortium of life sciences venture capital firms and would like to welcome both Gilde Healthcare as an investor in Inari and Geoff Pardo as a Board member,” said Bill Hoffman, President and Chief Executive Officer. “We will use these funds to support and accelerate our commercial, clinical and technology development programs.”

“There is a significant need to improve outcomes for the millions of patients suffering from VTE,” added Geoff Pardo of Gilde Healthcare.  “We have been impressed by the Inari team, the progress they’ve made to date and their vision to transform the treatment of VTE.”